» Articles » PMID: 34662441

Glycoforms of Human Prostate-specific Membrane Antigen (PSMA) in Human Cells and Prostate Tissue

Overview
Journal Prostate
Date 2021 Oct 18
PMID 34662441
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: N-glycosylation is a ubiquitous and variable posttranslational modification that regulates physiological functions of secretory and membrane-associated proteins and the dysregulation of glycosylation pathways is often associated with cancer growth and metastasis. Prostate-specific membrane antigen (PSMA) is an established biomarker for prostate cancer imaging and therapy.

Methods: Mass spectrometry was used to analyze the distribution of the site-specific glycoforms of PSMA in insect, human embryonic kidney, and prostate cancer cells, and in prostate tissue upon immunoaffinity enrichment.

Results: While recombinant PSMA expressed in insect cells was decorated mainly by paucimannose and high mannose glycans, complex, hybrid, and high mannose glycans were detected in samples from human cells and tissue. We noted an interesting spatial distribution of the glycoforms on the PSMA surface-high mannose glycans were the dominant glycoforms at the N459, N476, and N638 sequons facing the plasma membrane, while the N121, N195, and N336 sites, located at the exposed apical PSMA domain, carried primarily complex glycans. The presence of high mannose glycoforms at the former sequons likely results from the limited access of enzymes of the glycosynthetic pathway required for the synthesis of the complex structures. In line with the limited accessibility of membrane-proximal sites, no glycosylation was observed at the N51 site positioned closest to the membrane.

Conclusions: Our study presents initial descriptive analysis of the glycoforms of PSMA observed in cell lines and in prostate tissue. It will hopefully stimulate further research into PSMA glycoforms in the context of tumor staging, noninvasive detection of prostate tumors, and the impact of glycoforms on physicochemical and enzymatic characteristics of PSMA in a tissue-specific manner.

Citing Articles

In-silico structural and functional analysis of nonsynonymous single nucleotide polymorphisms in human gene.

Tondar A, Irfan M, Sanchez-Herrero S, Athar H, Haqqi A, Bepari A In Silico Pharmacol. 2025; 13(1):32.

PMID: 40018382 PMC: 11861814. DOI: 10.1007/s40203-025-00319-3.


Site-Specific Intact N-Linked Glycopeptide Characterization of Prostate-Specific Membrane Antigen from Metastatic Prostate Cancer Cells.

Mackay S, Hitefield N, Oduor I, Roberts A, Burch T, Lance R ACS Omega. 2022; 7(34):29714-29727.

PMID: 36061737 PMC: 9435049. DOI: 10.1021/acsomega.2c02265.


Site-specific glycosylation of SARS-CoV-2: Big challenges in mass spectrometry analysis.

Campos D, Girgis M, Sanda M Proteomics. 2022; 22(15-16):e2100322.

PMID: 35700310 PMC: 9349404. DOI: 10.1002/pmic.202100322.

References
1.
Evans M, Smith-Jones P, Wongvipat J, Navarro V, Kim S, Bander N . Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011; 108(23):9578-82. PMC: 3111331. DOI: 10.1073/pnas.1106383108. View

2.
Knedlik T, Navratil V, Vik V, Pacik D, Sacha P, Konvalinka J . Detection and quantitation of glutamate carboxypeptidase II in human blood. Prostate. 2014; 74(7):768-80. DOI: 10.1002/pros.22796. View

3.
Horoszewicz J, Leong S, Kawinski E, Karr J, Rosenthal H, Chu T . LNCaP model of human prostatic carcinoma. Cancer Res. 1983; 43(4):1809-18. View

4.
Ristau B, OKeefe D, Bacich D . The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2013; 32(3):272-9. PMC: 3972351. DOI: 10.1016/j.urolonc.2013.09.003. View

5.
Han S, Woo S, Kim Y, Suh C . Impact of Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018; 74(2):179-190. DOI: 10.1016/j.eururo.2018.03.030. View